Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

Bio2RDF identifier

NCT01097941

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01097941

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01097941

acronym [clinicaltrials_vocabulary:acronym]

H1N1Children

http://www.w3.org/2001/XMLSchema#string

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

51

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01097941 arm group 7c8b53bd7b4381f91d47610648e81ea5 [clinicaltrials_resource:NCT01097941/arm-group/7c8b53bd7b4381f91d47610648e81ea5]

NCT01097941 arm group f88d41fc4672cac1fc12b9b52e9de850 [clinicaltrials_resource:NCT01097941/arm-group/f88d41fc4672cac1fc12b9b52e9de850]

NCT01097941 arm group fdf3d37c7f0f022bae1c2e016e23e0d5 [clinicaltrials_resource:NCT01097941/arm-group/fdf3d37c7f0f022bae1c2e016e23e0d5]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:ca1954f55de6b13c270f49787460e895

brief summary [clinicaltrials_vocabulary:brief-summary]

A total of 51 children ...... isbane/57/07 reference virus.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:6068e85e25b27e70a90ac2d5c577590e]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:c0fabea4154e7b3de2267ddd2014dbee]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:f2feaff6fd0faf36398531a8473ea097]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:1d85f3350fdaf242ea3ec317e0032ecd]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:32e14d66d4639b2e39438c493b77a172]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:468164c0d8903bf2b31c06360f77bc05]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:9023538e5018185b906345a925324275]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:931dc96b83c2dfc372ae92bd4cd0fa92]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:a8b11706261a1748e29c81f3e4031ce4]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:b00689dec93b75d8b28a2b7746ac9c43]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:b282309525d7f87bf4da5545325ad36e]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:ddb6e0c7072bc4d5870f0dc75faa6a5c]

The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C nasal swabs obtained at days 2 post vaccination [clinicaltrials_resource:dfc7457545fe7dcdf180ef1af908faa7]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

completion date [clinicaltrials_vocabulary:completion-date]

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

The study will be condu ...... d TCID50 on MDCK cells.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01097941 [clinicaltrials_resource:afcc313f4174bb69a065b08636f236e3]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live [clinicaltrials_resource:0b6ba93cfdf33ed1239e2fb937e01113]

Live Attenuated H1N1 Influenza Vaccine [clinicaltrials_resource:820dd9fd65fbf4169f6e3ae2c9bfc20a]

Influenza A (H1N1) 2009 Monovalent Vaccine [clinicaltrials_resource:a7c4245bf5b73babcd1aa4bd80f3f8c0]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

H1N1

http://www.w3.org/2001/XMLSchema#string

Influenza

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2010-10-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

location [clinicaltrials_vocabulary:location]

University of Rochester Medical Center, Vaccine Research Unit Room 3-5000 [clinicaltrials_resource:43929fef32a6f6cbe620fbd88367e63b]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01097941

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

3

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Evaluation of the Effect of Ag ...... Influenza Vaccines in Children

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

URMC 09-007

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

John J Treanor, MD [clinicaltrials_resource:ce42e31a6d475bb2fc9cc6a1388c5cf9]

overall status [clinicaltrials_vocabulary:overall-status]

Terminated [clinicaltrials_resource:fba9c4daa2dd29d1077d32d965320ac1]

oversight [clinicaltrials_vocabulary:oversight]

United States: Institutional Review Board [clinicaltrials_resource:b46c5f1ee626ee51e33e6c048a7b19f6]

phase [clinicaltrials_vocabulary:phase]

Phase 4 [clinicaltrials_resource:ec41833bc88cd90619c4d85c549688bd]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reference [clinicaltrials_vocabulary:reference]

10501238 [pubmed:10501238]

16971435 [pubmed:16971435]

17050593 [pubmed:17050593]

17301299 [pubmed:17301299]

19423871 [pubmed:19423871]

19745214 [pubmed:19745214]

19745216 [pubmed:19745216]

5773321 [pubmed:5773321]

6997969 [pubmed:6997969]

7975853 [pubmed:7975853]

responsible party [clinicaltrials_vocabulary:responsible-party]

John Treanor, MD, Department of Internal Medicine, Division of Infectious Diseases, University of Rochester Medical Center [clinicaltrials_resource:8a0f58ff63bf429116dbc1d87a4996a5]

source [clinicaltrials_vocabulary:source]

University of Rochester [clinicaltrials_resource:a2ee82f5298e76bec3e878b4f0918a4f]

start date [clinicaltrials_vocabulary:start-date]

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01097941 study design [clinicaltrials_resource:706c020733a12c16b5ffa8f30eb17663]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01097941

verification date [clinicaltrials_vocabulary:verification-date]

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

why stopped [clinicaltrials_vocabulary:why-stopped]

Live H1N1 vaccine expired and unable to get new supply

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials:NCT01097941

http://www.w3.org/2001/XMLSchema#string

title

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children

@en